MARKET

EIGR

EIGR

Eiger Biopharma
NASDAQ
7.02
-0.37
-5.01%
Closed 19:51 10/05 EDT
OPEN
6.92
PREV CLOSE
7.39
HIGH
7.20
LOW
6.74
VOLUME
593.25K
TURNOVER
--
52 WEEK HIGH
10.02
52 WEEK LOW
3.530
MARKET CAP
308.65M
P/E (TTM)
-2.8709
1D
5D
1M
3M
1Y
5Y
A strong fall COVID booster campaign could save 90,000 U.S. lives and avoid more than 936,000 hospitalizations, study finds
A strong fall COVID booster campaign could save about 90,000 people living in the U.S. from dying of the virus and avoid more than 936,000 hospitalizations, according to a new study by the Commonwealth Fund.
marketwatch.com · 18h ago
Eiger BioPharma Shuns Plans For FDA Emergency Use Nod For COVID-19 Treatment
Following FDA feedback, Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) will not submit an emergency use authorization (EUA) application of peginterferon lambda for mild-to-moderate COVID-19. Following Eiger's press release in September, the company submitted ...
Benzinga · 21h ago
11 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Bionano Genomics (NASDAQ:BNGO) stock increased by 9.8% to $2.24. The company's market cap stands at $649.9 million.
Benzinga · 22h ago
Eiger BioPharmaceuticals Provides Update on Plans for Emergency Use Authorization Application Following FDA Feedback
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that, following feedback from the U.S....
PR Newswire · 22h ago
Eiger Says It Will Not Submit EUA Application for Peginterferom Lambda for COVID-19 Following FDA Feedback; Shares Down Pre-Bell
Eiger Says It Will Not Submit EUA Application for Peginterferom Lambda for COVID-19 Following FDA Feedback; Shares Down Pre-Bell
MT Newswires · 1d ago
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) is a favorite amongst institutional investors who own 61%
Every investor in Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) should be aware of the most powerful shareholder...
Simply Wall St. · 09/28 10:41
Starbucks To $94? Here Are 5 Other Price Target Changes For Wednesday
Citigroup raised the price target on Starbucks Corporation (NASDAQ: SBUX) from $90 to $94. Citigroup analyst Jon Tower maintained a Neutral rating on the stock. Starbucks shares fell 0.1% to $84.50 in pre-market trading.
Benzinga · 09/07 12:02
BTIG Maintains Buy on Eiger BioPharmaceuticals, Lowers Price Target to $48
BTIG analyst Robert Hazlett maintains Eiger BioPharmaceuticals (NASDAQ:EIGR) with a Buy and lowers the price target from $57 to $48.
Benzinga · 09/07 11:20
More
About EIGR
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development of therapies to treat and cure Hepatitis Delta Virus (HDV), the severe form of viral hepatitis, and other serious diseases. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV and Covid-19, Avexitide in Post-Bariatric Hypoglycemia (PBH) and Avexitide in Congenital Hyperinsulinism (CHI). Lambda is a late-stage, type III, interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections. Avexitide is a peptide, which is developing as a treatment for congenital hyperinsulinism (HI). It is also developing lambda as an out-patient treatment for patients with mild and moderate COVID-19. The Company is also developing Avexitide as a treatment for post-bariatric hypoglycemia (PBH).

Webull offers kinds of Eiger Biopharmaceuticals Inc stock information, including NASDAQ:EIGR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EIGR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EIGR stock methods without spending real money on the virtual paper trading platform.